[rfinney]

7 February 2019 Lancet paper on Tisotumab vedotin trial here : https://www.thelancet.com/journals/lanonc/article/PIIS1470-2... (entitled: "Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial")

Tisotumab vedotin is a first-in-human antibody–drug conjugate that is directed against tissue factor expressed on the cell surface of tumour cells to deliver a clinically validated toxic payload to tumours. [...] Tisotumab vedotin is comprised of a fully human monoclonal antibody specific for tissue factor conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. .... The study was funded by Danish and US biotech companies Genmab and Seattle Genetics

This Lancet paper references this 2014 Cancer Research paper: https://www.ncbi.nlm.nih.gov/pubmed/24371232?dopt=Abstract (http://cancerres.aacrjournals.org/content/74/4/1214.long) : "An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors"

Seattle Genetics page on Tisotumab Vedotin : http://www.seattlegenetics.com/pipeline/tisotumab-vedotin

Our [antibody-drug conjugate] technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer.

Interestingly, Seattle Genetics stock is down 12% on Friday: https://finance.yahoo.com/quote/SGEN ("cuz earnings"). Genmab was up 0.69% : https://finance.yahoo.com/quote/GEN.CO